SEOUL, South Korea, Dec. 15, 2025 — Lunit (KRX: 328130), a provider of AI for cancer diagnostics and precision oncology, has entered a collaboration with Daiichi Sankyo (TSE: 4568) to integrate Lunit SCOPE digital pathology products across two oncology research and development programs.
Daiichi Sankyo will apply Lunit SCOPE solutions, including SCOPE universal IHC (uIHC) for quantitative immunohistochemistry analysis and SCOPE IO for immune phenotyping and spatial analysis, to accelerate biomarker discovery and enhance translational research. The tools will be used to explore novel biomarkers, support precision patient stratification and potentially enrich future clinical trials for select oncology assets.
The collaboration will include exploratory research projects and analyses across two oncology programs and multiple cancer types, with the potential to inform trial designs, biomarker strategies and clinical development plans.
“Lunit SCOPE was built to unlock hidden insights from pathology slides—quantifying the tumor microenvironment, predicting molecular profiles and generating data-rich features to inform trial design,” said Brandon Suh, CEO of Lunit. “SCOPE uIHC is now enabling the next generation of IHC-based biomarkers. By working with Daiichi Sankyo, we are embedding these capabilities into translational and clinical research, enabling faster biomarker discovery and more precise patient stratification.”
About Lunit
Founded in 2013, Lunit develops clinically validated AI solutions for cancer detection and precision oncology. Its offerings span medical imaging, breast health and biomarker analysis, including the FDA-cleared Lunit INSIGHT suite and the Lunit SCOPE platform used in research partnerships for biomarker research and companion diagnostic development. Lunit serves more than 10,000 sites in over 65 countries and is headquartered in Seoul.
Leave a Reply